Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele

Journal of Alzheimer's Disease

Volumn 37, Issue 2, 2013, Pages 421-428

  Qiu, Wei Qiao ^a   Mwamburi, Mkaya ^b   Besser, Lilah M ^c   Zhu, Haihao ^a   Li, Huajie ^d   Wallack, Max ^a   Phillips, Leslie ^e   Qiao, Liyan ^f   Budson, Andrew E ^a   Stern, Robert ^a   Kowall, Neil ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e Urban Indian Health Institute   (United States)

^f TSINGHUA UNIVERSITY YUQUAN HOSPITAL   (China)

Author keywords

Alzheimer's disease; angiotensin converting enzyme (ACE) inhibitor; apolipoprotein E4 allele (ApoE4)

Indexed keywords

APOLIPOPROTEIN E4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC RISK; HETEROZYGOTE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOLIPOPROTEIN E4; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; PHARMACOGENETICS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84883803181     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130716     Document Type: Article

References (36)

1. Burgess E (2010) Reviewing the benefits of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy-are they drug specific or class specific? Can J Cardiol 26(Suppl E), 15E-19E.
2. Norris S, Weinstein J, Peterson K, Thakurta S (2010) Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final Report. Oregon Health & Science University, Portland, O.R.
3. Todd S, McGuinness B, Passmore AP (2010) Designing appropriate clinical trials to assess ACEI use and cognitive decline in older adults with hypertension. Arch Intern Med 170, 107.
4. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S (2011) Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: Analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 10, 43-53.
5. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC Jr (2009) Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: Results from the Cardiovascular Health Study. Arch Intern Med 169, 1195-1202.
6. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME (2009) Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 7, 250-261.
7. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM (2011) Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26, 699-708.
8. Qiu WW, Lai A, Mon T, Mwamburi M, Taylor W, Rosenzweig J, Kowall N, Stern R, Zhu H, Steffens DC (2013) Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele. Am J Geriatr Psychiatry, pii: S1064-S7481(12)00057-7. doi: 10.1016/j.jagp.2012.08.017
9. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90, 1977-1981.
10. Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM (2011) Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. Neurology 76, 1078- 1084.
11. Tanzi RE, Bertram L (2001) New frontiers in Alzheimer's disease genetics. Neuron 32, 181-184.
12. Baehner FL, Lee M, Demeure MJ, Bussey KJ, Kiefer JA, Barrett MT (2011) Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy. J Surg Oncol 103, 563-573.
13. Beekly DL, Ramos EM, van Belle G, Deitrich W, Clark AD, Jacka ME, KukullWA (2004) The National Alzheimer's Coordinating Center (NACC) Database: An Alzheimer disease database. Alzheimer Dis Assoc Disord 18, 270-277.
14. Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA (2007) The national Alzheimer's coordinating center (NACC) database: The uniform data set. Alzheimer Dis Assoc Disord 21, 249-258.
15. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, GalaskoD, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, KukullWA (2006) The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord 20, 210-216.
16. Chai SY, Zhuo J, Mendelsohn FA(1993) Localization of components of the renin-angiotensin system and site of action of inhibitors. Arzneimittel- Forschung 43, 214-221.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, StadlanEM(1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services Task force on Alzheimer's disease. Neurology 34, 939-944.
18. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, Sudha S (2002) The public health impact of Alzheimer's disease, 2000-2050: Potential implication of treatment advances. Ann Rev Public Health 23, 213-231.
19. Todd S, McGuinness B, Passmore AP (2010) Prevention of dementia by ACE inhibitors and angiotensin receptor blockers - potential but not proven. Int J Clin Pract 64, 1595- 1598.
20. Hajjar IM, Keown M, Lewis P, Almor A (2008) Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease:Anobservational study. Am J Alzheimers Dis Other Dement 23, 77-83.
21. Sudilovsky A, Cutler NR, Sramek JJ, Wardle T, Veroff AE, Mickelson W, Markowitz J, Repetti S (1993) A pilot clinical trial of the angiotensin- converting enzyme inhibitor ceranapril in Alzheimer disease. Alzheimer Dis Assoc Disord 7, 105-111.
22. Jouquey S, Mathieu MN, Hamon G, Chevillard C (1995) Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats. Neuropharmacology 34, 1689-1692.
23. Tan J, Wang JM, Leenen FH (2005) Inhibition of brain angiotensin- converting enzyme by peripheral administration of trandolapril versus lisinopril inWistar rats. Am J Hypertens 18, 158-164.
24. Akatsu H, Ogawa N, Kanesaka T, Hori A, Yamamoto T, Matsukawa N, MichikawaM(2011) Higher activity of peripheral blood angiotensin-converting enzyme is associated with lateronset of Alzheimer's disease. J Neurol Sci 300, 67-73.
25. Farrer LA, Sherbatich T, Keryanov SA, Korovaitseva GI, Rogaeva EA, Petruk S, Premkumar S, Moliaka Y, Song YQ, Pei Y, Sato C, Selezneva ND, Voskresenskaya S, Golimbet V, Sorbi S, Duara R, Gavrilova S, St George-Hyslop PH, Rogaev EI (2000) Association between angiotensinconverting enzyme and Alzheimer disease. Arch Neurol 57, 210-214.
26. Bertram L (2009) Alzheimer's disease genetics current status and future perspectives. Int Rev Neurobiol 84, 167-184.
27. Hajjar I, Kritchevsky S, Newman AB, Li R, Yaffe K, Simonsick EM, Lipsitz LA (2010) Renin angiotensin system gene polymorphisms modify angiotensin-converting enzyme inhibitors' effect on cognitive function: The health, aging and body composition study. J Am Geriatr Soc 58, 1035-1042.
28. Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM (1991) Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol 200, 289-292.
29. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S, Kehoe PG (2009) Angiotensin-converting enzyme levels and activity in Alzheimer's disease: Differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 1, 163-177.
30. Wang B, Jin F, Yang Z, Lu Z, Kan R, Li S, Zheng C, Wang L (2006) The insertion polymorphism in angiotensinconverting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease. J Mol Neurosci 30, 267-271.
31. Lucatelli JF, Barros AC, Silva VK, Machado Fda S, Constantin PC, Dias AA, Hutz MH, de Andrade FM (2011) Genetic influences on Alzheimer's disease: Evidence of interactions between the genes APOE, APOC1 and ACE in a sample population from the South of Brazil. Neurochem Res 36, 1533-1539.
32. Gearing M, Mori H, Mirra SS (1996) Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 39, 395-399.
33. Holtzman DM (2004) In vivo effects of ApoE and clusterin on amyloid-betametabolism and neuropathology. J Mol Neurosci 23, 247-254.
34. Gopal K, Nagarajan P, Raj TA, Jahan P, Ganapathy HS, Mahesh Kumar MJ (2011) Effect of dietary beta carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E-/- mice. J Thrombosis Thrombolysis 32, 343-355.
35. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340, b5465.
36. Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM (2012) The effects of ramipril in individuals at risk for Alzheimer's disease: Results of a pilot clinical trial. J Alzheimers Dis 32, 147-156.